Genomic strategy for targeting therapy in castration-resistant prostate cancer.

Publication Type:

Journal Article

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 27, Issue 12, p.2022-9 (2009)

Keywords:

2009, Androgen Antagonists, androgens, Center-Authored Paper, Clinical Research Division, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, GENOMICS, Genomics Core Facility, Human Biology Division, Humans, Male, Neoplasms, Hormone-Dependent, Oligonucleotide Array Sequence Analysis, Orchiectomy, Prostatic Neoplasms, Protein Kinase Inhibitors, Pyrimidines, Receptors, Androgen, Shared Resources, Signal Transduction, src-Family Kinases, Thiazoles

Abstract:

Despite treatments which lower circulating androgens, advanced prostate cancers often maintain androgen receptor (AR) signaling. The variable response to secondary hormonal manipulations in men with castrate-resistant prostate cancer (CRPC) creates a compelling need for strategies to individualize therapy based on the molecular features of each patient's tumor.